Workflow
三星医疗(601567):2025年中报点评:提质增效效果显著,业绩基本符合市场预期

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in the first half of 2025 is in line with market expectations, with significant improvements in quality and efficiency [8] - The company has achieved robust growth in its power distribution business, particularly in overseas markets, which is becoming a key growth driver [8] - The rehabilitation hospital business faces some pressure, but long-term demand remains strong [8] - The company has effectively controlled costs, leading to a notable reduction in expenses [8] - The long-term outlook for the overseas power distribution market is positive, with strong competitive advantages [8] Financial Summary - Total revenue for 2023 is projected at 11,463 million, with a year-on-year growth of 25.99% [1] - Net profit attributable to shareholders for 2023 is expected to be 1,904 million, reflecting a year-on-year increase of 100.79% [1] - The earnings per share (EPS) for 2023 is estimated at 1.35 yuan, with a price-to-earnings (P/E) ratio of 18.20 [1] - The company anticipates total revenue of 18,034 million in 2025, with a year-on-year growth of 23.51% [1] - The net profit attributable to shareholders for 2025 is projected at 2,511 million, with a year-on-year growth of 11.14% [1] - The EPS for 2025 is expected to be 1.79 yuan, with a P/E ratio of 13.80 [1]